Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplontersen PK/PD in Healthy Chinese Volunteers
NCT06527755Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eplontersen in Transthyretin amyloidosis (ATTR), sponsored by AstraZeneca. Primary endpoints: Maximum Observed Concentration at Day 92, Time to Maximal Concentration at Day 92 and 3 more. Started Aug 2024; status: completed.
02
Drugs
eplontersen
03
Conditions
Transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT06527755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527755.